- Home
- XBIO vs PRFX Comparison
XBIO vs PRFX Comparison
Compare XBIO & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- PRFX
- Stock Information
- Founded
- XBIO N/A
- PRFX 2007
- Country
- XBIO United States
- PRFX Israel
- Employees
- XBIO N/A
- PRFX N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- PRFX Health Care
- Exchange
- XBIO Nasdaq
- PRFX Nasdaq
- Market Cap
- XBIO 4.2M
- PRFX 3.6M
- IPO Year
- XBIO N/A
- PRFX 2020
- Fundamental
- Price
- XBIO $3.00
- PRFX $1.93
- Analyst Decision
- XBIO Hold
- PRFX Hold
- Analyst Count
- XBIO 1
- PRFX 1
- Target Price
- XBIO N/A
- PRFX N/A
- AVG Volume (30 Days)
- XBIO 8.8K
- PRFX 358.6K
- Earning Date
- XBIO 05-13-2025
- PRFX 06-13-2025
- Dividend Yield
- XBIO N/A
- PRFX N/A
- EPS Growth
- XBIO N/A
- PRFX N/A
- EPS
- XBIO N/A
- PRFX N/A
- Revenue
- XBIO $2,582,728.00
- PRFX N/A
- Revenue This Year
- XBIO $14.23
- PRFX N/A
- Revenue Next Year
- XBIO $7.14
- PRFX N/A
- P/E Ratio
- XBIO N/A
- PRFX N/A
- Revenue Growth
- XBIO 5.63
- PRFX N/A
- 52 Week Low
- XBIO $2.20
- PRFX $1.68
- 52 Week High
- XBIO $5.20
- PRFX $19.20
- Technical
- Relative Strength Index (RSI)
- XBIO 52.87
- PRFX 43.57
- Support Level
- XBIO $2.85
- PRFX $1.85
- Resistance Level
- XBIO $3.25
- PRFX $2.00
- Average True Range (ATR)
- XBIO 0.13
- PRFX 0.09
- MACD
- XBIO -0.01
- PRFX 0.01
- Stochastic Oscillator
- XBIO 40.48
- PRFX 42.11
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.